Advanced Search

 

Study ID Status Title Patient Level Data
S2B308E Completed Evaluation of sumatriptan in the treatment of migraine pain recurrence- extension.
S2B-341 Completed A double-blind, placebo-controlled, parallel group study to evaluate two dose levels (10mg and 20mg) of intranasal sumatriptan in the acute treatment of a migraine attack.
S2B-H27 Completed A study to determine whether ergotamine (0.25mg given intravenously) has any effect on the pharmacodynamics and pharmacokinetics of GR43175C in healthy subjects.
S2BP31 Completed The treatment of chronic tension-type headache with subcutaneous GR43175C – a placebo-controlled dose-comparison study.
S2BP33 Completed A study to investigate the effects on the coronary vasculature of the 5HT1-like receptor agonist, GR43175C, in subjects with existing coronary artery disease.
S2BP42 Completed A single-blind two-part study to rechallenge with subcutaneous GR43175C, patients who had previously experienced an adverse event involving discomfort or pain in the chest following GR43175C administration.
S2BP49 Completed A study to investigate the effects of subcutaneous GR43175C on the coronary vasculature in patients with existing or suspected coronary artery disease.
S2BS70 Completed Evaluation of up to two oral doses of sumatriptan (100mg) following acute treatment of migraine with subcutaneous sumatriptan (6mg).
S2BS75 Completed A double-blind, placebo-controlled, parallel-group study of 6mg + optional 6mg subcutaneous GR43175C administered using the Glaxo Autoinjector in the treatment of a migraine attack, with an optional, open, 6-month extension: An interim report on the double-blind phase.
S2BS77 Completed A double-blind, placebo-controlled, parallel group study of 6mg + optional 6 mg subcutaneous GR43175C (sumatriptan) administered using the Glaxo autoinjector during the aura phase of a migraine attack with an optional open six month extension.
S2BS78 Completed A double-blind, placebo-controlled, parallel group study of 6mg subcutaneous sumatriptan + optional 6mg subcutaneous sumatriptan administered using a novel cartridge system self-injector in slow developing migraine.
S2BT16 Completed A double-blind, placebo-controlled, crossover study to evaluate oral GR43175C 100 mg in the acute treatment of migraine.
S2BT27 Completed A double-blind study to compare oral GR43175C (100mg) with oral aspirin (900mg) plus metoclopramide (10mg) in the acute treatment of migraine over a six month period.
S2BT33 Completed An open design study to evaluate repeat-dose oral sumatriptan (100 mg plus optional 100 mg plus optional further 100 mg for recurrent headache) in the acute treatment of migraine attacks during a 24-month period.
S2BT57 Completed An open design study to evaluate the safety of rectal dosing with sumatriptan (25mg and optional 25mg dose for headache recurrence) in the acute treatment of all migraine attacks over a 12 month period.
S2CP46 Completed An in-clinic pilot study to examine the efficacy and safety of oral GR43175C (50mg or 100mg) for the acute treatment of migraine in adolescents.
S2CP81 Completed The acute treatment of episodic tension-type headache with oral GR43175C (100mg) – a double-blind, placebo-controlled, parallel group pilot study.
S2CT34 Completed A double-blind study to compare the efficacy of a repeat dose of oral GR43175C regimen (plus a further optional dose for recurrence) with placebo in the acute treatment of migraine.
S2CT37 Completed A double-blind study to compare the efficacy and safety or oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents.
S2CT40 Completed A double-blind study to compare the efficacy and safety of oral sumatriptan (50mg or 100mg) with placebo for the acute treatment of migraine in adolescents.
S2CT41 Completed Pre-emptive oral GR43175C treatment during a cluster headache period – (100mg tid for 7 days) – A double-blind, parallel group, placebo controlled study.
S2W20006 Completed A randomised, double-blind, placebo-controlled crossover study investigating the efficacy and safety of intermittent prophylactic treatment with oral naratriptan 1mg b.i.d. in women with pre-menstrual dysphoria. Study Listed on ClinicalStudyDataRequest.com
S2W30018 Completed An open study of the efficacy and tolerability of naratriptan in prophylactic treatment of pure menstrual migraine attacks.
S2W40010 Completed A randomised, double-blind, cross-over study to compare the patient preference of oral Naratriptan (Naramig) 2.5mg with Naproxen 500mg in patients dissatisfied with simple analgesics in the treatment of acute migraine.
S2W40012 Completed A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily asprophylactic treatment for menstrually-associated migraine.

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.